Newsroom.

AusBiotech showcase Australian biotechnology companies to Chinese investors at Hong Kong meeting of Asia Biotech Invest, a high-profile life science investment series that connects life science companies with the investment community.

Nine high-quality selected biotechnology and medical companies are already locked-in to present their investment proposition to potential partners and investors. Complimentary registration is available for qualified investors by contacting AusBiotech (details below). 

The event is to be held in May (5-6) at the Hong Kong Convention and Exhibition Centre. The OECD recently reported Hong Kong as the third largest global financial centre and with its unique relationship to China and is a major destination for investment events and a logical place for Australian companies and Chinese investors to meet.

Hong Kong, with its relationship with China, is developing as a pivotal hub in the Asia Pacific region, and this is especially important from an Australian perspective as a regional neighbour. Private investment by Chinese venture capitalists has burst forth in recent years. The average Chinese VC investment in life sciences is approximately $25 million, compared to $10 million from US investors – demonstrating the value that is seen in this area.

Presenting companies will include:

Biotron	Developers of revolutionary treatments for serious viral disease, including a pipeline of programs for first-in-class antiviral medicines.
Adherium	Global leader in the design and development of evidence-based digital health solutions.
4Dx	Specialises in respiratory diagnostics, including earlier detection and intervention of disease.
Nexvet Biopharma	Transforming the therapeutic market for companion animals.
GO Resources	Focusing on the sustainable production and supply of renewable and biodegradable raw materials.
Pregtech	Working with farmers to help them extract greater value out of their business, including a sensor that detects ovulation in dairy cows.
Provectus Biopharmaceuticals	Specialises in developing oncology and dermatology therapies to advance a new front in the fight against cancer.
Oncosil Medical	Developers of a patent-protected proprietary medical device (class III) that creates a localised stream of beta radiation.
Uni-BioScience Group	A leading biopharmaceutical company with unparalleled expertise in delivering innovative solutions to the Chinese healthcare market focusing on diabetes, ophthalmology and dermatology.

The event will also feature an exhibition area, enabling companies to display additional information, and the BioInvest Partnering System, streamlining delegates’ ability to discuss investment opportunities. The program will provide exclusive insight into Asian life science investment, including specialist advice for Hong Kong fund managers and Chinese investment trends. See all the companies that attended last year: http://ausbiotechinvestment.com.au/uploads/Investor%20List%20for%20web.pdf

Asia Biotech Invest is part of AusBiotech’s Asia Investment Series, which will also include the Singapore Biotech Invest, to be held Tuesday 3 May at the Singapore Exchange.

AusBiotech is Australia’s biotechnology industry organisation, working on behalf of over 3,000 members in the areas of human health, medical devices, food technology, agriculture, environmental and industrial biotechnology for 30 years. AusBiotech Investment offers a comprehensive series of national and international investor events as a global platform for Australian life sciences companies to showcase their company’s offering for partnership and investment.

-ENDS-

ausbiotechinvestment.com.au

 
Media enquiries: Lorraine Chiroiu, AusBiotech’s Chief Industry Affairs Officer,
lchiroiu@ausbiotech.org/ P: +61 (0) 3 9828 1414 /M: +61 (0) 429 801 118

Event enquiries: Amelia Lundstrom, Investment Events Coordinator
alundstrom@ausbiotech.org/ P: +61 (0) 3 9828 1435